MXPA98003802A - Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas. - Google Patents

Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.

Info

Publication number
MXPA98003802A
MXPA98003802A MXPA98003802A MX9803802A MXPA98003802A MX PA98003802 A MXPA98003802 A MX PA98003802A MX PA98003802 A MXPA98003802 A MX PA98003802A MX 9803802 A MX9803802 A MX 9803802A MX PA98003802 A MXPA98003802 A MX PA98003802A
Authority
MX
Mexico
Prior art keywords
preparations
thyroid hormone
disclosed
methods
making same
Prior art date
Application number
MXPA98003802A
Other languages
English (en)
Spanish (es)
Inventor
L Thomas Charles Iii
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA98003802A publication Critical patent/MXPA98003802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA98003802A 1995-11-14 1996-11-14 Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas. MXPA98003802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US673895P 1995-11-14 1995-11-14
US1731496P 1996-05-13 1996-05-13
PCT/IB1996/001330 WO1997017951A1 (en) 1995-11-14 1996-11-14 Stabilized thyroid hormone preparations and methods of making same

Publications (1)

Publication Number Publication Date
MXPA98003802A true MXPA98003802A (es) 2005-04-29

Family

ID=26675995

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA98003802A MXPA98003802A (es) 1995-11-14 1996-11-14 Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.

Country Status (12)

Country Link
US (2) US5955105A (OSRAM)
EP (1) EP0861073B1 (OSRAM)
JP (1) JP2000500155A (OSRAM)
AT (1) ATE271863T1 (OSRAM)
AU (1) AU712217B2 (OSRAM)
BR (1) BR9611306A (OSRAM)
CA (1) CA2235707A1 (OSRAM)
DE (1) DE69633018T2 (OSRAM)
ES (1) ES2224184T3 (OSRAM)
MX (1) MXPA98003802A (OSRAM)
PT (1) PT861073E (OSRAM)
WO (1) WO1997017951A1 (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
DE19830246A1 (de) 1998-07-07 2000-01-13 Merck Patent Gmbh Pharmazeutische Zubereitung
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3699000A (en) * 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
AU783656B2 (en) * 1999-09-02 2005-11-24 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
JP4902928B2 (ja) * 2000-05-24 2012-03-21 大塚製薬株式会社 製剤の安定化方法
EP1157682A1 (en) * 2000-05-25 2001-11-28 Cilag AG Blister package for topiramate tablets
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AU2002243557B2 (en) 2001-01-26 2006-01-05 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
DK1413331T3 (da) 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
BR0207297A (pt) * 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
ITMI20011401A1 (it) 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
AU2002332507A1 (en) * 2001-08-10 2003-02-24 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
WO2003028624A2 (en) * 2001-08-14 2003-04-10 King Pharmaceuticals, Inc Levothyroxine compositions and methods
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030194437A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Cmax properties
US7101569B2 (en) * 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030191185A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
MXPA04006631A (es) * 2002-01-07 2004-11-10 Abbott Gmbh & Co Kg Cristalizacion de aminoacidos utilizando agitacion ultrasonica.
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
AU2003268078A1 (en) * 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
WO2004041208A2 (en) * 2002-11-05 2004-05-21 New River Pharmaceuticals Inc. Controlled absorption of mixed thyroyd hormone formulations
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ES2344294T3 (es) * 2003-05-02 2010-08-24 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Preparacion farmaceutica solida que contiene sales de levotiroxina y/o liotironina.
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
US20060008512A1 (en) * 2004-07-07 2006-01-12 Hooge Danny M Composition and methods for improved animal performance
JP5173832B2 (ja) * 2006-01-06 2013-04-03 インターベツト・インターナシヨナル・ベー・ベー 濃縮液体甲状腺ホルモン組成物
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
GB2457710A (en) * 2008-02-25 2009-08-26 Andrew Nicolaou Thyroxine and its use in weight loss and obesity treatment
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CA2805958A1 (en) * 2009-08-04 2011-02-10 Haren Treasurer Greater utility with thyroid hormone
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
KR101800229B1 (ko) * 2011-04-08 2017-12-20 브라코 이미징 에스.피.에이. 3,5-디요오도-ｏ-[3-요오도페닐]-ｌ-티로신의 황산화 유도체의 제조 방법
EP2750664A1 (en) 2011-08-30 2014-07-09 Fresenius Kabi USA, LLC Levothyroxine formulations
US8779000B1 (en) * 2013-07-20 2014-07-15 Nilesh Parikh Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
EP2932963A1 (en) * 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical dosage forms comprising Levothyroxine sodium
US11154498B2 (en) 2015-07-22 2021-10-26 Leiutis Pharmaceuticals Pvt. Ltd. Stabilized liquid formulation of levothyroxine
US11364196B2 (en) 2015-11-04 2022-06-21 Leiutis Pharmaceuticals Pvt. Ltd. Levothyroxine formulations for oral use
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same
TW202227047A (zh) * 2020-10-09 2022-07-16 日商Ａｓｋａ製藥股份有限公司 甲狀腺荷爾蒙的製劑化方法
WO2023088976A1 (en) 2021-11-16 2023-05-25 Tap Pharmaceuticals, Ag Orodispersible levothyroxine compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
CH658188A5 (de) * 1984-03-23 1986-10-31 Ciba Geigy Ag Lagerstabile schnellzerfallende pharmazeutische presslinge.
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE69224809T2 (de) * 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
DE4318577A1 (de) * 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine

Also Published As

Publication number Publication date
PT861073E (pt) 2004-10-29
EP0861073B1 (en) 2004-07-28
EP0861073A1 (en) 1998-09-02
DE69633018T2 (de) 2004-12-09
AU712217B2 (en) 1999-11-04
BR9611306A (pt) 1999-12-28
ES2224184T3 (es) 2005-03-01
US6056975A (en) 2000-05-02
DE69633018D1 (de) 2004-09-02
CA2235707A1 (en) 1997-05-22
ATE271863T1 (de) 2004-08-15
JP2000500155A (ja) 2000-01-11
AU7584996A (en) 1997-06-05
WO1997017951A1 (en) 1997-05-22
US5955105A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
MXPA98003802A (es) Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.
AU7038587A (en) Amino acid chelated compositions
BG101781A (bg) Твърд препарат, съдържащ активно вещество
AU3044492A (en) Sustained release thyroactive composition
IE882671L (en) Stabilised human protein formulation
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
HUP9802287A2 (hu) Cinkkel és kívánt esetben lizinnel vagy kalciumionnal előkezelt növekedési hormont tartalmazó stabilizált gyógyszerkészítmény
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
ATE83924T1 (de) Ibuprofen-cyclodextrin-einschlusskomplexe enthaltende pharmazeutische zubereitungen.
IE842579L (en) Cimetidine containing compositions
AU3394689A (en) Pharmaceutical compositions
EP0208519A3 (en) Solubilized composition of hardly-soluble pharmaceutical product
CA2085258A1 (en) Method for growth promotion of animals and powder compositions containing killed microbial cells of bacteria belonging to genus clostridium
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
AU566228B2 (en) Compressed hydroxybutryic acid polymer retarded release vehicle
IE822064L (en) Composition containing human insulin and c-peptide
EP0397147A3 (en) Stable solutions of rebeccamycin analog and preparation thereof
MX9500130A (es) Preparaciones orales en semi-pasta.
IL127851A0 (en) Inhibition of TNF activity
AU6922891A (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
GB2258397A (en) Pharmaceutical compositions containing amethocaine
JPS57200361A (en) "indomethacin(r)" pharmaceutical with low irritant action
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.
JPS57156412A (en) Preparation containing dextromethorphan hydrobromide

Legal Events

Date Code Title Description
GB Transfer or rights